Massachusetts General Hospital Receives NIH Grant for Low Risk In Vivo Diagnosis of IPF with Optical Imaging
Massachusetts General Hospital Receives a 2020 NIH Grant for $179,280 for Low Risk In Vivo Diagnosis of IPF with Optical Imaging. The principal investigator is Lida Hariri. Below is a summary of the proposed work. Idiopathic pulmonary fibrosis (IPF) is a progressive, ultimately fatal form of idiopathic interstitial pneumonitis (IIP), with a 3 year survival rate of 0%. Diagnostic certainty of IPF is critical to patient management and therapeutic decision-making. Two new FDA-approved therapies, pirfenidone and nintedanib, have been shown to slow disease progression in IPF and brought new hope to IPF patients. Due to their high costs, side ...
